Sydney-based biotech NeuClone has signed a major licensing agreement and joint development partnership with The Serum Institute of India covering the manufacturing of 10 biosimilar drugs.
Under the agreement, NeuClone will use its NeuMAX cell line development platform to manufacture and supply 10 biosimilar monoclonal antibody drugs. The Serum Institute, the world’s largest vaccine producer, will provide its biologics manufacturing capability.
The drugs will have targets including cancer and autoimmune disorders, and each will address markets worth hundreds of millions to billions of dollars, the companies said.
As part of the partnership, NeuClone will retain the licence to the biosimilars for the markets of the US, Europe, Canada, Australia, Taiwan, Japan and South Korea. The company said it will seek partnerships with large pharmaceutical and generics companies in these markets.
The Serum Institute will meanwhile receive an exclusive worldwide licence for marketing and sales of the drug in the rest of the world. The institute plans to use the collaboration to deliver biosimilar versions of expensive drugs to markets of patients that have been unable to afford the real thing.
This article has been extracted from http://lifescientist.com.au, please click on this link to read the article in full http://lifescientist.com.au/content/biotechnology/news/neuclone-signs-biosimilar-deal-with-serum-institute-972901099
Montash is a multi-award winning, global IT recruitment firm. Specialising in permanent and contract positions across mid-senior appointments which cover a wide range of industry sectors and IT functions, including:
ERP, BI & Data, Information Security, IT Architecture & Strategy, Scientific Technologies, Demand IT and Business Engagement, Digital and E-commerce, Infrastructure and Service Delivery, Project and Programme Delivery.
With offices based in London, Montash has completed assignments in over 30 countries and has appointed technical professionals from board level to senior and mid-management in permanent and contract roles.